

Best of ASH-2016 & 21st Annual CME in Hematology

With International faculty



Thurs-Sat, 19th - 21st Jan, 2017

Hotel ITC Grand Central, Parel, Mumbai, India



Mumbai Hematology Group

With compliments from

**Executive Committee
Mumbai Hematology Group**

President

Dr. M.B. Agarwal

Vice-President

Dr. Farah Jijina

Secretary

Dr Swati Kanakia

Treasurer

Dr. Brijesh Arora

Members

Dr Shubhangi Agale

Dr. S.D. Banavali

Dr. Roshan Colah

Dr. Mukesh Desai

Dr. S. Khodaiji

Dr. Vrinda Kulkarni

Dr. Mamta Manglani

Dr. Navin Khattry

Dr Chandrakala S

Dr. Asha Shah

Dr Shrimati Shetty

Best of ASH-2016 & 21st Annual CME in Hematology

Dear Colleague,

Best of ASH-2016 (which will be held in San Diego in December 2016) and 21st Annual CME in Hematology will be held under the aegis of Mumbai Hematology Group (MHG) at Hotel ITC Grand Central, Parel, Mumbai from Thursday to Saturday, 19th to 21st January 2017.

We have already engaged some of the top international faculty from US and Europe for this event. Emphasis will be on the newer data that will be presented during ASH-2016. We will be discussing both basics as well as applied aspects (Diagnostic and Therapeutic). Pediatric subjects will also be covered.

As usual, Team from Nucleus (Mr. Rajesh Sharma, Mr. Yash Agarwal, Mr. Kalpesh Pambhar and others) has been appointed for managing the event.

The meeting will begin with lunch on day 1 and end with lunch on day 3. You can arrive in the morning of day 1 and leave by late afternoon on day 3. A large number of rooms have been booked at same hotel for 2 nights i.e. Thursday and Friday (19th & 20th of January 2017).

Early registration for this event will be the key to make it an economical affair.

Looking forward to your kind participation which will make this academic feast a grand event.

Your sincerely



Dr M B Agarwal, MD

Hematologist & Hemato-Oncologist
President - Mumbai Hematology Group



Mumbai Hematology Group

Best of ASH-2016 & 21st Annual CME in Hematology

International faculty



Mumbai Hematology Group



Dr. Flora Peyvandi, MD, PhD

Professor of Internal Medicine
Director of the Angelo Bianchi Bonomi Haemophilia
and Thrombosis Centre
Fondazione IRCCS Ca' Granda
Ospedale Maggiore Policlinico
Milan, Italy



Dr. Sabine Eichinger

Professor of Medicine
Department of Internal medicine
Medical University of Vienna
Karl Landsteiner Institute of Thrombosis Research,
Vienna, Austria



Dr Henrik Hasle

Professor
Department of Paediatrics,
Aarhus University Hospital Skejby,
Aarhus, Denmark



Dr Ajay Nooka

Assistant Professor
Division of Bone Marrow Transplant
Department of Hematology and Medical Oncology,
Winship Cancer Institute of Emory University,
Atlanta, Georgia, USA

Best of ASH-2016 & 21st Annual CME in Hematology

International faculty



Mumbai Hematology Group




Dr. Naval Daver

Assistant Professor
Leukemia Department
MD Anderson Cancer Center
Houston, Tx, USA



Dr. Ghulam Mufti

Director of King's College Hospital NHS Foundation Trust
Professor of Haemato-oncology,
Clinical Director of Pathology
Head of the Department of Haematology
King's College Hospital, London, UK



John Mascarenhas, MD

Tisch Cancer Institute, Division of Hematology/Oncology
Icahn School of Medicine at Mount Sinai
New York, USA



Dr A C Newland

Professor
Department of Haematology
Barts Health NHS trust - The Royal London Hospital
London, UK

Best of ASH-2016 & 21st Annual CME in Hematology

International faculty



Mumbai Hematology Group



Dr Neal Young, MD

Senior Investigator

Cell Biology Section, Hematology Branch

National Heart, Lung and Blood Institute

National Institutes of Health, Bethesda, MD, USA



Dr Genoveffa Franchini, MD

Center for Cancer Research

National Cancer Institute (NCI)

National Institutes of Health

Bethesda, MD, USA



Dr Mala K Talekar, MD

Attending Physician, Cancer Immunotherapy Frontier Program

Division of Oncology & Blood and Marrow Transplantation

Department of Pediatrics

The Children's Hospital of Philadelphia,

Philadelphia, USA

Best of ASH-2016 & 21st Annual CME in Hematology

Who will speak on what !

- Dr Ajay K Nooka**
1. Definition and management of high risk myeloma: progress in the last decade
 2. Newer Therapeutic options for R/R myeloma: focus on Carfilzomib
 3. ASH 2016 updates in myeloma
- Dr Ghulam Mufti**
1. Low risk MDS - What is new ?
 2. High risk MDS - What is new ?
 3. Pathobiology of MDS - What is new ?
- Dr Naval Daver**
1. A Look at Immunotherapeutic Drug Development in leukemia and MDS: 2017
 2. AML: Highlights of Molecular and Immune Therapies from ASH 2016
 3. The future of Hypomethylating Agents in AML: Building Optimal Combinations
- Dr John Mascarenhas**
1. Ruxolitinib the past, present and what to expect in the future
 2. Case based clinical approach to modern management of ET, PV and PMF, as well as MPN related AML
 3. Updates on MPN from ASH 2016
- Dr Hasle Henrik**
1. Myelodysplastic and Myeloproliferative Disorders of Childhood
 2. Management of childhood AML
 3. Late complications in survivors of AML
- Dr Mala Talekar**
1. Chimeric Antigen Receptor (CAR) Modified T cell Therapy for relapsed / refractory pediatric leukaemias
- Dr Neal Young**
1. Immunology of acquired aplastic anemia: pathophysiology and treatment
 2. Telomere disease and other constitutional marrow failure syndromes in adults
 3. Eltrombopag as stem cell stimulation in bone marrow failure
- Dr A C Newland**
1. How do I treat ITP in 2017 ?
 2. A to Z about Romiplostim in the treatment of ITP
 3. Platelets : What was new in ASH-2016 ?
- Dr Flora Peyvandi**
1. Thrombotic thrombocytopenic purpura - Advances
 2. Hemophilia : Diagnosis, treatment and complications - The past and future
 3. Bleeding disorders - Advances in treatment
- Dr Sabine Eichinger**
1. All about DOACs
 2. Recurrent DVT - All that a clinician should know
 3. Cancer related thrombosis
- Dr Gnovetta Fanchini**
1. From animal studies to men and back: Prospective in the development of a vaccine for HIV

Best of ASH-2016 & 21st Annual CME in Hematology

Scientific agenda

Day 1 : Thursday, 19th January 2017

Time	Speaker	Subject
09.00 am onwards	Registration	
09.00 am - 09.45 am	Meet the professor	Marrow failure syndromes (Neal Young)
10.00 am - 10.45 am	Meet the professor	AML, MDS, MPN (Naval Daver)
11.00 am - 11.45 am	Meet the professor	Bleeding & Thrombotic Disorders (Flora Peyvandi & Sabine Eichinger)
12.00 noon	Lunch	
12.45 pm - 01.00 pm	Opening ceremony	Purvish Parikh, Sudeep Gupta, Shashi Apte, Jina Bhattacharya
01.00 pm - 01.30 pm	Neal Young, USA	Immunology of acquired aplastic anaemia : Pathophysiology and treatment
01.30 pm - 02.00 pm	Naval Daver, USA	A Look at Immunotherapeutic Drug Development in leukemia and MDS: 2017
02.00 pm - 02.30 pm	Gnoveffa Fanchini, USA	From animal studies to men and back: Prospective in the development of a vaccine for HIV
02.30 pm - 02.45 pm	Discussion	
02.45 pm - 03.15 pm	Coffee	
03.15 pm - 03.45 pm	Sabine Eichinger, Vienna	Cancer related thrombosis- Advances
03.45 pm - 04.15 pm	Flora Peyvandi, Italy	Thrombotic thrombocytopenic purpura - Advances
04.15 pm - 04.45 pm	Sabine Eichinger, Vienna	All about DOACs in 2017
04.45 pm - 05.15 pm	Flora Peyvandi, Italy	Hemophilia : Diagnosis, treatment & complications - The past & future
05.15 pm - 05.30 pm	Discussion	
05.30 pm - 06.00 pm	High Tea	
06.00 pm - 06.30 pm	Mala Talekar, USA	CAR-T Therapy for R/R Pediatric Leukaemias
06.30 pm - 07.00 pm	S D Banavali, Mumbai	Pediatric ALCL - Newer aspects
07.00 pm - 07.30 pm	Reena Nair, Kolkata	All lymphomas cannot be CHOPped
07.30 pm - 08.00 pm	Satya Dattatreya Palanki, Hyderabad	Obinutuzumab scores over Rituximab
08.00 pm - 08.15 pm	Discussion	
08.15 pm onwards	Dinner	

Best of ASH-2016 & 21st Annual CME in Hematology

Scientific agenda

Day 2 : Friday, 20th January 2017

Time	Speaker	Subject
08.00 am - 08.45 am	Meet the professor	Multiple Myeloma (Ajay Nooka)
09.00 am - 09.30 am	Ajay Nooka, USA	Definition and management of high risk myeloma: progress in the last decade
09.30 am - 10.00 am	John Mascarenhas, USA	Ruxolitinib: The past, present and what to expect in the future
10.00 am - 10.30 am	Ghulam Mufti, London	Pathobiology of MDS - What is new ?
10.30 am - 10.45 am	Discussion	
10.45 am - 11.15 am	Coffee	
11.15 am - 11.45 am	Flora Peyvandi, Italy	Bleeding disorders - Advances in treatment
11.45 am - 12.15 pm	A C Newland, London	How do I treat ITP in 2017 ?
12.15 pm - 12.45 pm	Sabine Eichinger, Vienna	Recurrent DVT - All that a clinician should know !
12.45 pm - 01.00 pm	Discussion	
01.00 pm - 01.45 pm	Lunch	
01.45 pm - 02.15 pm	Hasle Henrik, Denmark	Myelodysplastic and Myeloproliferative Disorders of Childhood
02.15 pm - 02.45 pm	Naval Daver, USA	The future of Hypomethylating Agents in AML: Building Optimal Combinations
02.45 pm - 03.15 pm	Hasle Henrik, Denmark	Management of childhood AML
03.15 pm - 03.30 pm	Discussion	
03.30 pm - 04.00 pm	Coffee	
04.00 pm - 04.45 pm	Best of three abstracts, India	
04.45 pm - 05.15 pm	Ghulam Mufti, London	Low risk MDS - What is new ?
05.15 pm - 05.45 pm	Ajay Nooka, USA	Newer Therapeutic options for R/R MM: focus on Carfilzomib
05.45 pm - 06.15 pm	John Mascarenhas, USA	Case based clinical approach to modern management of ET, PV & PMF, as well as MPN related AML
06.15 pm - 06.30 pm	Discussion	
06.30 pm - 07.00 pm	High Tea	
07.00 pm - 08.30 pm	Symposium : CML (Sponsors : BMS)	
08.30 pm onwards	Dinner	

Best of ASH-2016 & 21st Annual CME in Hematology

Scientific agenda

Day 3 : Saturday, 21st January 2017

Time	Speaker	Subject
08.00 am - 08.45 am	Meet the professor	Platelets (A C Newland)
09.00 am - 09.30 am	A C Newland, London	A to Z about Romiplostim in the treatment of ITP
09.30 am - 10.00 am	Neal Young, USA	Eltrombopag as stem cell stimulator in marrow failure
10.00 am - 10.30 am	A C Newland, London	ASH-2016 updates in platelet disorders
10.30 am - 10.45 am	Discussion	
<hr/>		
10.45 am - 11.15 am	Coffee	
<hr/>		
11.15 am - 11.45 am	Neal Young, USA	Telomere disease and other constitutional marrow failure syndromes in adults
11.45 am - 12.15 pm	Hasle Henrik, Denmark	Late complications in survivors of AML
12.15 pm - 12.45 pm	Navel Daver, USA	ASH-2016 updates in AML: Molecular and Immune Therapies
12.45 pm - 01.00 pm	Discussion	
<hr/>		
01.00 pm - 01.45 pm	Lunch	
<hr/>		
01.45 pm - 02.15 pm	John Mascarenhas, USA	ASH-2016 updates in MPN
02.15 pm - 02.45 pm	Ajay Nooka, USA	ASH-2016 updates in MM
02.45 pm - 03.15 pm	Ghulam Mufti, London	ASH-2016 updates in MDS
03.15 pm - 03.30 pm	Discussion	
03.30 pm - 04.00 pm	Closing ceremony	M B Agarwal, Swati Kanakia
<hr/>		
04.00 pm	High Tea	
<hr/>		

Best of ASH-2016 & 21st Annual CME in Hematology

Know your faculty

- 1. Dr Adrian C Newland**
 - Dr Adrian Newland is Professor of Haematology at Barts Health NHS Trust, London, UK and at Queen Mary University of London.
 - His clinical interests are in immune haematology and he jointly developed the National Registry for Immune Thrombocytopenia to collect comprehensive epidemiological and clinical data.
 - His group is undertaking research into the molecular and immune basis of autoimmune disease and he has an active clinical research programme in novel treatments.
 - He helped develop the ITP Clinical Network in the UK and he has developed guidelines and clinical studies in ITP.
 - He is Chair of the National Institute for Health and Care Excellence (NICE) Diagnostic Assessment Programme.
 - He is ex-President of the British Society for Haematology, was President of the Royal College of Pathologists from 2005–2008, and President of the International Society of Hematology (ISH) from 2016 - 2016.
 - He is Senior Editor of Hematology, the journal of the ISH, and he has published over 300 peer-reviewed papers in international journals including Blood, the British Journal of Haematology, The Lancet and the American Journal of Hematology.
 - He is current advisor to NHS England on pathology

- 2. Dr Henrik Hasle**
 - He is professor in pediatric hematology/oncology at the department of Pediatrics, Aarhus University Hospital Skejby in Aarhus, Denmark.
 - He received his doctor of medicine degree from Odense University, Denmark.
 - He trained in epidemiology, hematology and pediatrics at Odense University Hospital, where he also completed a research fellowship in pediatric oncology with a thesis on myelodysplastic syndrome.
 - Since 2000, he was consultant and associate professor in pediatric hematology/oncology at Aarhus University Hospital Skejby in Aarhus Denmark and was subsequently awarded full professor in 2009.
 - He is a founding member of the European Working group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) and served as chairman of the group 1998-2002.
 - He was the chairman of the AML group of the Nordic Society for Pediatric Hematology and Oncology (NOPHO) 2002 to 2010 and continues as responsible for the data managing of the NOPHO-AML protocols.
 - He is the chairman of the International-BFM-AML group from 2016.
 - He is the author or coauthor of more than 210 peer reviewed journal articles mainly dealing with myeloid leukemia in children, genetic predisposition to cancer, and late effects after cancer therapy.

Best of ASH-2016 & 21st Annual CME in Hematology

Know your faculty

- 3. Dr John Mascarenhas**
- He is an Associate Professor of Medicine at the Icahn School of Medicine at Mount Sinai (ISMMS) and a member of the Tisch Cancer Institute in New York City.
 - As a clinical investigator in malignant hematology with a focus in translational research involving Myeloproliferative Neoplasms (MPNs), he is primarily responsible for the clinical trials portion of the Myeloproliferative Disorders Program at ISMMS.
 - He is also the Principal Investigator (PI) of the clinical trials project within the National Cancer Institute sponsored Myeloproliferative Disorder Research Consortium (MPD-RC).
 - He has served as PI or Study Chair of multiple investigator-initiated and industry-sponsored early and late phase clinical trials evaluating innovative approaches to the treatment of MPNs.
- 4. Dr Naval Daver**
- He is an Assistant Professor in the Department of Leukemia at MD Anderson Cancer Center in Houston, Texas.
 - He completed his medical school from Grant Medical College and Sir J J group of hospitals, Mumbai followed by a residency and fellowship in hematology-oncology from Baylor College of Medicine.
 - He has published more than 100 peer reviewed manuscripts focusing on emerging therapies and clinical trials in AML and myelofibrosis.
 - He is PI or Co-PI for over 25 ongoing multicenter or investigator initiated clinical trials with a focus in development of immune (Checkpoints, Vaccines, Monoclonals) and Molecular Therapies in AML and Myelofibrosis.
 - He is a member of the MDACC Hematology-Oncology Fellowship Steering committee and Course Director for the Leukemia Department.
 - He is a PI, Co-PI or collaborator on extramural grants including Leukemia Lymphoma Society Therapy Acceleration Program, Ladies Leukemia League, MDACC Leukemia SPORE, and MDACC CPRIT grant.

Best of ASH-2016 & 21st Annual CME in Hematology

Know your faculty

5. Dr Mala K Talekar

- She completed her medical school training from Grant Medical College & Sir JJ Group of Hospitals, Mumbai, India, with honors in 2001.
- She then did a residency in Pediatrics from Sir HN Hospital & Research Center, Mumbai, India with DCH and DNB certifications.
- Her passion to obtain advanced training in Pediatric Hematology Oncology led her to United States and after finishing a Pediatric residency from Children's Hospital of Philadelphia (CHOP) in 2011.
- She completed fellowship training in Pediatric Hematology Oncology & Bone Marrow Transplant at Penn State Hershey Children's Hospital in 2014.
- During her fellowship, the death of a teenaged patient due to a rare form of lymphoma despite multiple forms of treatment led her to pursue bench research evaluating TRAIL-based agents in hematologic malignancies.
- She found that a newly discovered small molecule TIC10 (now ONC201) could induce apoptotic death in a broad panel of lymphoma cell lines.
- Her early success helped her obtain prestigious research grants like American Society of Clinical Oncology (ASCO)'s Conquer Cancer Foundation's Young Investigator Award and Live Like Bella Childhood Cancer Foundation's Research funding to support her ongoing research for further drug development of this exciting molecule.
- She then joined the Children's Hospital of Philadelphia's Cancer Immunotherapy Frontier Program as an Attending Physician where she is an investigator on clinical trials evaluating Chimeric Antigen Receptor (CAR) Modified T Cell therapy in relapsed/ refractory pediatric leukemias/ lymphomas.
- Due to their unprecedented success, CAR-T based immunotherapies have been designated as a Novel Breakthrough Therapy for pediatric ALL and are on their way to potentially becoming the next standard of care for pediatric ALL.
- In a research role, she also actively pursues translational research in further developing the drug ONC201 for several pediatric cancers with a goal to bringing it to a clinical trial in pediatric malignancies.

Best of ASH-2016 & 21st Annual CME in Hematology

Know your faculty

- 6. Dr Genoveffa Franchini**
- She is a renowned Retrovirologist who has pioneered research on oncogenes and human retroviruses (HTLVs and HIVs) at the Center of Cancer Research at the National Institute of Health, Bethesda, MD, USA.
 - As a Chief of the Animal Models and Retroviral Vaccines Section, her lab has been working on HTLV-1 that causes leukemia and a progressive spastic myelopathy as well as in HIV pathogenesis and vaccine development using non-human primate models.
 - One of the vaccines developed and tested in Dr. Franchini's laboratory is in clinical trials in 16,000 volunteers in Thailand. Dr. Franchini's laboratory genetically characterized SIV (Nature 1987) and defined the regulatory function of HIV-1/2 and SIV genes (Science 1986, 1990).
 - Dr. Franchini serves the scientific field through editorial duties and has been an Associate Editor for Blood, Mucosal Immunology, and AIDS Reviews, and is in frequent demand to review manuscripts for journals including: Journal of Clinical Investigation, Journal of Experimental Medicine, Journal of Immunology, Journal of Infectious Diseases, Journal of Virology, Nature Medicine, Nature Reviews Immunology, Science and Oncogene.
 - She serves on scientific committees, faculties, and advisory and review boards in intramural and extramural capacities.
 - Dr. Franchini's major research interests are: (1) to investigate how HTLV-1 proteins subvert cellular and physiological pathways of T cells and lead to their transformation and (2) to develop strategies for preventive vaccines and therapeutic vaccines for HIV-1.

Best of ASH-2016 & 21st Annual CME in Hematology

Know your faculty

7. Dr. Flora Peyvandi

- She is Professor of Internal Medicine at the University of Milan and the Director of the Angelo Bianchi Bonomi Hemophilia and Thrombosis Centre, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy.
- She received her medical degree from the University of Milan, Italy, is certified in Haematology and was awarded PhDs from the Maastricht University, The Netherlands and the University of Milan, Italy for her research in the field of rare bleeding disorders.
- Her basic and medical science research has focused on the investigation of coagulation disorders.
- Her research in the prevalence and mechanism of coagulation disorders aims at developing cost-effective treatment for the widespread treatment of patients.
- She has authored and co-authored more than 310 scientific publications that have been published across well-known specialized journals (IF of about 1600, H index WoS of 43) and also 18 chapters in various books.
- Since 1999, she has been invited as an expert speaker at more than 100 national and international meetings and congresses.
- She has been the successful recipient of more than 40 project grants funded by Italian and International organizations and she was the principal investigator of the Establishment of an European Network of Rare Bleeding Disorders programme.
- She participates in clinical, educational and research activities in different parts of the world and she was Chair of the International Society of Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee on Factor VIII, Factor IX and Rare Coagulation Disorders.
- She is member of the ISTH council, member of the Executive Committee of the World Federation of Hemophilia (WFH), member of the executive committee of the European Association for Haemophilia and Allied Disorders (EAHAD) and member of the Medical Advisory Group of the European Hemophilia Consortium (EHC).
- In 2014 she was awarded the "Great Hippocrates " that is delivered to Italian medical researcher of the year.

Best of ASH-2016 & 21st Annual CME in Hematology

Know your faculty

- 8. Dr. Sabine Eichinger**
- She received her medical and scientific training at the Dept. of Medicine I at the Medical University of Vienna, and at the Beth Israel Hospital, Harvard Medical School, in Boston, USA.
 - She is associate professor of medicine and head of the anticoagulation clinic at the Medical University Hospital of Vienna, Austria.
 - She has broad clinical and scientific experience in the field of thrombosis and haemostasis and is an expert in designing and conducting clinical studies.
 - She has vast experience in investigating mechanism of action of procoagulants and anticoagulants and in evaluating the role of risk factors and biomarkers for thrombotic disease.
 - She serves as the principal investigator of several interventional studies on anticoagulation in patients with venous thromboembolism or atrial fibrillation.
 - She is past-chairman of the Scientific and Standardization Subcommittee of the International Society on Thrombosis and Haemostasis (ISTH) and served as a Council Member of the Society.
 - She is a recipient of several international and national academic awards.
- 9. Dr Neal Young**
- Dr Young is the Chief of the Hematology Branch of the National Heart, Lung, and Blood Institute.
 - He graduated from Harvard College and Johns Hopkins School of Medicine
 - He did medical residency at the Massachusetts General Hospital and training in hematology at Washington University in St. Louis.
 - Post-doctoral fellowships in biochemistry and molecular biology were at the National Institutes of Health, with Drs. Alan Schechter and Arthur Nienhuis.
 - His research interests are bone marrow failure, normal and abnormal hematopoiesis, viral infections of marrow cells, autoimmunity, and mechanisms of genomic instability and leukemogenesis.
 - His work includes clinical trials in his bone marrow failure clinic in Bethesda (immunosuppression, telomere modulation, stem cell stimulation), basic science in virology, immunology, and cell biology (parvovirus B19, telomerase gene mutations, immune pathogenesis of marrow failure), and epidemiology (the largest population based study of aplastic anemia, in Thailand).
 - He has published almost 400 original research articles, more than 150 reviews and chapters, and 10 monographs.
 - His laboratory has trained dozens of world leaders in hematology.

Best of ASH-2016 & 21st Annual CME in Hematology

Poster-Presentation

- Abstracts are invited for poster presentation during Best of ASH-2016
- Please note that these will be e-Posters
- Following are the guidelines for the same



- An e-Poster is an electronic version of a poster presentation.
- The e-Poster presentations must be prepared in PowerPoint.
- As an e-Poster presenter you are asked to prepare a PowerPoint presentation up to a maximum of 08 slides.
- It may include text, figures, charts, tables, images, and artwork but an e-Poster digital presentation does not include any audio, video or animation.
- Do not use special fonts which are not part of the standard PowerPoint package as this will cause problems while uploading your file.
- Set the slide size of the page to “On-screen show” and landscape orientation in the page set-up section.
- Portrait orientation will not be displayed properly.
- Three best abstracts will be invited to do oral presentation.
- **Last date for receiving abstract of the poster is Thursday, 15th December 2016.**

Recommended Format:

Slide 1 Title + Authors	Slide 2 Introduction	Slide 3 Objectives	Slide 4 Materials & Methods
Slide 5 - 7 Results			Slide 8 Conclusions

Registration fee

Category	Up to 31st December 2016	Spot Registration
Fellow / Trainee / Resident	₹ 9000 /-	₹ 21000 /-
All other delegates	₹ 11000 /-	₹ 21000 /-

All registrations after 31st December 2016 will be considered as **spot registrations**

- Note:**
- Registration is mandatory for all participants.
 - Registrations will be restricted to first 150 delegates
 - Registration fee includes lunch on all 3 days.

Accommodation

Accommodation is available at **Hotel ITC Grand Central, Parel**, Mumbai which is the venue of the meeting. It will be available only for 2 nights i.e. from 12 noon on Thursday, 19th January 2017 to 12 noon on Saturday, 21st January 2017.

There are 2 options :

- a) Single room, single occupancy : ₹ 13,000/- per night.
b) Double room, double occupancy : ₹ 15,000/- per night.

Note: For double room - double occupancy, delegates have to forward 2 names themselves.

All payments are to be made in favour of : **Mumbai Hematology Group**

Refund policy

Refunds towards registration will be done only until 15th December 2016 after deducting 50% towards administrative charges. Refunds towards accommodation will be done after deducting one day hotel stay charges. The refunds will be done only on receipt of email indicating the same and one month after the conference is over.

Online registration

For online registration, you can go to the following link
<http://in.eregnow.com/ticketing/register/ASH2016ANNUALCME>

Address for all correspondence : **Dr M B Agarwal**, Course coordinator,
Best of ASH-2016
Mumbai Hematology Group
Hematology Clinic, Ghamat Lodge, 804-A,
Dr B Ambedkar Road, Dadar TT, Mumbai 400014, India.
Cell : +91 9820024850,
Email ID : mbagarwal1@hotmail.com
mhgpho@hotmail.com
Website : www.bestofash2016.com

Event Manager :

Nucleus

Mr. Rajesh Sharma : + 91 9374073512
Mr. Yash Agarwal : + 91 8790612727
Mr. Kalpesh Pambhar : + 91 9601608846